109 related articles for article (PubMed ID: 10871312)
1. A molecular model of agonist and nonpeptide antagonist binding to the human V(1) vascular vasopressin receptor.
Thibonnier M; Coles P; Conarty DM; Plesnicher CL; Shoham M
J Pharmacol Exp Ther; 2000 Jul; 294(1):195-203. PubMed ID: 10871312
[TBL] [Abstract][Full Text] [Related]
2. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
Nakamura S; Yamamura Y; Itoh S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Ogawa H; Shinohara T; Kan K; Tanada Y; Teramoto S; Sumida T; Nakayama S; Sekiguchi K; Kambe T; Tsujimoto G; Mori T; Tominaga M
Br J Pharmacol; 2000 Apr; 129(8):1700-6. PubMed ID: 10780976
[TBL] [Abstract][Full Text] [Related]
4. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
5. Molecular modelling of the vasopressin V2 receptor/antagonist interactions.
Czaplewski C; Kaźmierkiewicz R; Ciarkowski J
Acta Biochim Pol; 1998; 45(1):19-26. PubMed ID: 9701492
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Br J Pharmacol; 1998 Dec; 125(7):1463-70. PubMed ID: 9884074
[TBL] [Abstract][Full Text] [Related]
7. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
[TBL] [Abstract][Full Text] [Related]
8. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
9. Distinct mechanisms of action of V1 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells.
Jamil KM; Watanabe T; Nakao A; Okuda T; Kurokawa K
Biochem Biophys Res Commun; 1993 Jun; 193(2):738-43. PubMed ID: 8390252
[TBL] [Abstract][Full Text] [Related]
10. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
Cotte N; Balestre MN; Aumelas A; Mahé E; Phalipou S; Morin D; Hibert M; Manning M; Durroux T; Barberis C; Mouillac B
Eur J Biochem; 2000 Jul; 267(13):4253-63. PubMed ID: 10866830
[TBL] [Abstract][Full Text] [Related]
11. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
12. Charged residues of the conserved DRY triplet of the vasopressin V1a receptor provide molecular determinants for cell surface delivery and internalization.
Hawtin SR
Mol Pharmacol; 2005 Oct; 68(4):1172-82. PubMed ID: 16049168
[TBL] [Abstract][Full Text] [Related]
13. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
Guillon G; Pena A; Murat B; Derick S; Trueba M; Ventura MA; Szeto HH; Wo N; Stoev S; Cheng LL; Manning M
J Pept Sci; 2006 Mar; 12(3):190-8. PubMed ID: 16130178
[TBL] [Abstract][Full Text] [Related]
14. Binding sites and transduction process of the cholecystokininB receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis.
Jagerschmidt A; Guillaume N; Roques BP; Noble F
Mol Pharmacol; 1998 May; 53(5):878-85. PubMed ID: 9584214
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.
Serradeil-Le Gal C; Wagnon J; Garcia C; Lacour C; Guiraudou P; Christophe B; Villanova G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1993 Jul; 92(1):224-31. PubMed ID: 8392086
[TBL] [Abstract][Full Text] [Related]
16. The binding of propranolol at 5-hydroxytryptamine1D beta T355N mutant receptors may involve formation of two hydrogen bonds to asparagine.
Glennon RA; Dukat M; Westkaemper RB; Ismaiel AM; Izzarelli DG; Parker EM
Mol Pharmacol; 1996 Jan; 49(1):198-206. PubMed ID: 8569707
[TBL] [Abstract][Full Text] [Related]
17. Cysteine residues are involved in structure and function of melanocortin 1 receptor: Substitution of a cysteine residue in transmembrane segment two converts an agonist to antagonist.
Frändberg PA; Doufexis M; Kapas S; Chhajlani V
Biochem Biophys Res Commun; 2001 Mar; 281(4):851-7. PubMed ID: 11237737
[TBL] [Abstract][Full Text] [Related]
18. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
Gimpl G; Postina R; Fahrenholz F; Reinheimer T
Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
[TBL] [Abstract][Full Text] [Related]
19. Model structures of the N-methyl-D-aspartate receptor subunit NR1 explain the molecular recognition of agonist and antagonist ligands.
Moretti L; Pentikäinen OT; Settimo L; Johnson MS
J Struct Biol; 2004 Mar; 145(3):205-15. PubMed ID: 14960371
[TBL] [Abstract][Full Text] [Related]
20. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
Dautzenberg FM; Wille S
Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
